Search Results - "Volz, H P"

Refine Results
  1. 1

    Controlled clinical trials of hypericum extracts in depressed patients--an overview by Volz, H P

    Published in Pharmacopsychiatry (01-09-1997)
    “…In Germany, hypericum extracts are among the most widely prescribed antidepressants. Additionally, many preparations of St. John's wort are sold on the free…”
    Get more information
    Journal Article
  2. 2

    Efficacy of Silexan in Patients with a Major Depressive Episode – First Results from a Multi-centre, Double-blind, Randomised, Placebo- and Reference-controlled Phase III Trial by Kasper, S, Seifritz, E, H-P Volz

    Published in European psychiatry (01-08-2024)
    “…IntroductionSilexan [1], an essential oil from Lavandula angustifolia flowers, is the active substance of a medicinal product for oral use in the treatment of…”
    Get full text
    Journal Article
  3. 3

    Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial by Volz, H P, Kieser, M

    Published in Pharmacopsychiatry (01-01-1997)
    “…101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment…”
    Get more information
    Journal Article
  4. 4

    Wie Sie nächtliche Leidenszeiten lindern können by Volz, H. -P.

    Published in MMW Fortschritte der Medizin (01-05-2016)
    “…Schmerzsyndrome und Schlafstörungen verstärken sich gegenseitig: Schmerzen rauben den Schlaf, Schlafmangel wiederum erhöht die Schmerzempfindung. Wie Sie…”
    Get full text
    Journal Article
  5. 5

    Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective by Altamura, A. C., Armadoros, D., Jaeger, M., Kernish, R., Locklear, J., Volz, H.-P.

    Published in Current medical research and opinion (01-08-2008)
    “…ABSTRACT Objective: To assess European psychiatrists' prescribing behaviour and their perceived need for access to a wide range of atypical antipsychotics for…”
    Get full text
    Journal Article
  6. 6

    Clinical trials with sigma ligands by Volz, H-P, Stoll, K D

    Published in Pharmacopsychiatry (01-11-2004)
    “…So far, sigma-ligands have been investigated for several indications in human studies in functional diarrhea as a model of somatoform disorder (igmesine),…”
    Get more information
    Journal Article
  7. 7

    Impaired sensory processing in male patients with schizophrenia—a magnetoencephalographic study of auditory mismatch detection by Kreitschmann-Andermahr, I, Rosburg, T, Meier, T, Volz, H.-P, Nowak, H, Sauer, H

    Published in Schizophrenia research (11-01-1999)
    “…The generation of mismatch negativity (MMN) as a component of auditory evoked event-related brain potentials has been reported previously to be severely…”
    Get full text
    Journal Article
  8. 8

    Time estimation in schizophrenia: an fMRI study at adjusted levels of difficulty by Volz, Hans-Peter, Nenadic, Igor, Gaser, Christian, Rammsayer, Thomas, Häger, Frank, Sauer, Heinrich

    Published in Neuroreport (12-02-2001)
    “…fMRI was performed in nine male schizophrenia patients and 15 healthy male controls during an auditory time estimation (timing), a frequency (i.e. pitch)…”
    Get full text
    Journal Article
  9. 9

    Decreased frontal activation in schizophrenics during stimulation with the Continuous Performance Test - a functional magnetic resonance imaging study by Volz, H.-P., Gaser, C., Häger, F., Rzanny, R., Pönisch, J., Mentzel, H.-J., Kaiser, W.A., Sauer, H.

    Published in European psychiatry (01-03-1999)
    “…The Continuous Performance Test (CPT) has become an essential constituent of the neuropsychological investigation of schizophrenia. Also, a vast number of…”
    Get full text
    Journal Article
  10. 10

    Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans by Kuhn, U D, Kirsch, M, Merkel, U, Eberhardt, A M, Wenda, B, Maurer, I, Härtter, S, Hiemke, C, Volz, H P, Balogh, A

    “…The noradrenaline-selective antidepressant reboxetine in vitro is a weak inhibitor of both cytochrome P450 (CYP) 2D6 and CYP3A4. Thus, in this study the…”
    Get full text
    Journal Article
  11. 11

    Cerebral Phosphate Metabolism in First-Degree Relatives of Patients With Schizophrenia by Klemm, Silke, Rzanny, Reinhard, Riehemann, Stephan, Volz, Hans-Peter, Schmidt, Beate, Gerhard, Uwe-Jens, Filz, Christina, Schönberg, Anke, Mentzel, Hans-Joachim, Kaiser, Werner A., Blanz, Bernhard

    Published in The American journal of psychiatry (01-06-2001)
    “…OBJECTIVE: Most phosphorus-31 magnetic resonance spectroscopy (31P-MRS) studies have described measures of lower membrane anabolism or greater catabolism in…”
    Get full text
    Journal Article
  12. 12

    Abnormalities of auditory evoked magnetic fields and structural changes in the left hemisphere of male schizophrenics : A magnetoencephalographic-magnetic resonance imaging study by HAJEK, M, HUONKER, R, BOEHLE, C, VOLZ, H.-P, NOWAK, H, SAUER, H

    Published in Biological psychiatry (1969) (01-10-1997)
    “…Functional and structural changes in 10 DSM-III-R male schizophrenics and 10 healthy volunteers were investigated using magnetoencephalographically (MEG)…”
    Get full text
    Journal Article
  13. 13

    31P-MR spectroscopy in children and adolescents with a familial risk of schizophrenia by Rzanny, R, Klemm, S, Reichenbach, J R, Pfleiderer, S O R, Schmidt, B, Volz, H-P, Blanz, B, Kaiser, W A

    Published in European radiology (01-04-2003)
    “…Based on a previous report [9] on alterations of membrane phosphorus metabolism in asymptomatic family members of schizophrenic patients, the aim of the…”
    Get full text
    Journal Article
  14. 14

    Cognitive stimulation with the Wisconsin Card Sorting Test: functional MR imaging at 1.5 T by Mentzel, H J, Gaser, C, Volz, H P, Rzanny, R, Häger, F, Sauer, H, Kaiser, W A

    Published in Radiology (01-05-1998)
    “…To determine whether functional magnetic resonance (MR) imaging can demonstrate a specific pattern of cerebral activation during cognitive stimulation by using…”
    Get more information
    Journal Article
  15. 15

    Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test — a functional MRI study on healthy volunteers and schizophrenics by Volz, Hans-Peter, Gaser, Christian, Häger, Frank, Rzanny, Reinhardt, Mentzel, Hans-Joachim, Kreitschmann-Andermahr, Ilonka, Kaiser, Werner Alois, Sauer, Heirich

    Published in Psychiatry research (31-10-1997)
    “…It has been demonstrated by single photon emission computed tomography (SPECT) and positron emission tomography (PET) that frontal brain regions are stimulated…”
    Get full text
    Journal Article
  16. 16

    Monoamine oxidase inhibitors: A perspective on their use in the elderly by VOLZ, H.-P, GLEITER, C. H

    Published in Drugs & aging (01-11-1998)
    “…Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's…”
    Get full text
    Journal Article
  17. 17

    P03-123 - Is escitalopram exchangeable by citalopram? A systematic survey by Volz, H.-P, Flürenbrock, W

    Published in European psychiatry (2011)
    “…Objective Efficacy differences between antidepressants have only been detected exceptionally (Bauer et al., 2009). Due to the fact that escitalopram is the…”
    Get full text
    Journal Article
  18. 18

    Silexan does not cause withdrawal symptoms even when abruptly discontinued by Gastpar, M., Müller, W. E., Volz, H. P., Möller, H. J., Schläfke, S., Dienel, A., Kasper, S.

    “…Objective: Subsequent to a randomised, double-blind, double dummy clinical trial assessing the efficacy of silexan compared to placebo and paroxetine in…”
    Get full text
    Journal Article
  19. 19

    Continuation and long-term maintenance treatment with Hypericum extract WS® 5570 after recovery from an acute episode of moderate depression — A double-blind, randomized, placebo controlled long-term trial by Kasper, S, Volz, H.P, Möller, H.J, Dienel, A, Kieser, M

    Published in European neuropsychopharmacology (01-11-2008)
    “…Abstract The efficacy and safety of Hypericum extract WS® 5570 in preventing relapse during 6 months' continuation treatment and 12 months' long-term…”
    Get full text
    Journal Article
  20. 20

    Gabapentin leads to remission of somatoform pain disorder with major depression by Maurer, I, Volz, H P, Sauer, H

    Published in Pharmacopsychiatry (01-11-1999)
    “…Gabapentin, a novel antiepileptic drug, is effective in the treatment of partial seizures with and without secondary generalization. Evidence suggests that it…”
    Get more information
    Journal Article